IMA901
immatics’ vaccine increases survival in kidney cancer
July 30, 2012Research and Development, Sales and Marketing IMA901, Vaccine, Yervoy, immatics, phase III
immatics’ investigational cancer vaccine has increased survival rates in patients with renal cell carcinoma. In a late-stage trial, the German …
Latest content
MedPharm appoints Jason Mieding as chief operating officer
November 8, 2026
Coriolis Pharma appoints Teun van der Heide as CEO
November 7, 2026
